Biogen reported its Q3 2020 financial results, highlighting that its total revenues had reached $3.3 million. However, this was a 6% decrease from the third quarter of 2019. In an effort to cull the financial loss, the company stated that it would be halting work on opicinumab, its experimental multiple sclerosis (MS) drug. According to the financial report, the Phase 2 AFFINITY study in patients with MS did not meet its primary or secondary endpoints, leading to the decision to stop development.
Despite missing the primary and secondary endpoints in the phase 2 SYNERGY study, the results of which were published in The Lancet Neurology in 2019, Biogen choose to move forward with the AFFINITY study and initiated enrollment in 2017.
Opicinumab is a human monoclonal antibody against LINGO-1, an inhibitor of oligodendrocyte differentiation and axonal regeneration.
About Multiple Sclerosis
Multiple Sclerosis (MS) is a disabling disease of the brain and spinal cord (central nervous system). In MS, the immune system attacks the protective sheath (myelin) that covers nerve fibers and causes communication problems between the brain and the rest of the body. Eventually, the disease can cause permanent damage or deterioration of the nerves.
Signs and symptoms of MS vary widely and depend on the amount of nerve damage and which nerves are affected. Some people with severe MS may lose the ability to walk independently or at all, while others may experience long periods of remission without any new symptoms.
There’s no cure for multiple sclerosis. However, treatments can help speed recovery from attacks, modify the course of the disease and manage symptoms.